Skip to content

Clinical Study of Liposomal Bupivacaine Combined with Ropivacaine for Brachial Plexus Block

Safety and Efficacy of Liposomal Bupivacaine Combined with Ropivacaine for Brachial Plexus Block

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500110324
Enrollment
Unknown
Registered
2025-10-11
Start date
2025-10-12
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative pain

Interventions

Trial group (Group B):Group B patients received either 15 mL of 0.886% bupivacaine liposome under ultrasound-guided supraclavicular approach for brachial plexus block, or 30 mL of 0.33% ropivacaine hy
Control group (L group):Group L patients received 15 mL of 0.33% ropivacaine hydrochloride for ultrasound-guided supraclavicular brachial plexus block, and 30 mL of 0.33% ropivacaine hydrochloride for

Sponsors

The first affiliated hostipal of nanchang university
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Before the trial, fully understand the nature, significance, and potential benefits of the trial, as well as the possible inconveniences and potential dangers Understand the research procedures and voluntarily sign the informed consent form in writing. 2.Patients scheduled for elective intramedullary nailing of forearm fractures; 3.No gender restrictions, aged 18-65 years; 4.BMI19.0~26.0kg/m^2; 5.The ASA (American Society of Anesthesiologists) physical status classification is I to II.

Exclusion criteria

Exclusion criteria: 1.The patient refuses to undergo brachial plexus block; 2.The patient has a history of specific allergic diseases (asthma, urticaria, eczema, etc.) or is known to be allergic bupivacaine; 3.The patient has a history of surgery on the neck or supraclavicular fossa on the surgical side; there is damage or infection in theillary and supraclavicular puncture areas; 4.The patient has abnormal coagulation function; 5.The patient has a history of chronic neuropathic pain. 6.Chronic opioid use (e.g., morphine sulfate extended-release tablets, oxycodone hydrochloride extended-release tablets, fentanyl transmal patches, etc.); 7.Surgical limb nerve function defect; 8.The patient has a history of mental illness; 9.The patient is concurrently enrolled in another clinical trial;

Design outcomes

Primary

MeasureTime frame
Visual analogue scale;

Secondary

MeasureTime frame
Resting NRS score;Duration of sensory and motor block;Incidence of adverse events of local anesthetic in patients;Postoperative opioid consumption and pain satisfaction;Incidence of adverse events of nerve block manipulation in patients;Incidence of postoperative nausea and vomiting and use of antiemetics;

Countries

China

Contacts

Public ContactHuang Jian

The first affiliated hostipal of nanchang university

122568589@qq.com+86 791 88695462

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026